Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT.
暂无分享,去创建一个
S. Alabed | D. Kiely | S. Rajaram | C. Hill | R. Condliffe | K. Dwivedi | M. Sharkey | M. Mamalakis | A. Thompson | James M Wild | Andrew J Swift | Liam Delaney | Christopher Johns | Alex Rothman
[1] S. Alabed,et al. A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension , 2023, Scientific Reports.
[2] M. Humbert,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.
[3] Robert A. Lewis,et al. Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease , 2022, ERJ Open Research.
[4] D. Kiely,et al. Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow , 2021, European Respiratory Journal.
[5] S. Rosenkranz,et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry , 2021, European Respiratory Journal.
[6] B. Maron,et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients , 2021, European Respiratory Journal.
[7] E. Hoffman,et al. Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review , 2021, Diagnostics.
[8] H. Olschewski. The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease , 2021, Diagnostics.
[9] Jonathan H. Chung,et al. Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation , 2021, Radiology. Cardiothoracic imaging.
[10] Robert A. Lewis,et al. Mild parenchymal lung disease is still lung disease , 2020, European Respiratory Journal.
[11] L. Harbaum,et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[12] M. Lidén,et al. Interobserver variability in high-resolution CT of the lungs , 2020, European journal of radiology open.
[13] Robert A. Lewis,et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension , 2020, European Respiratory Journal.
[14] R. Benza,et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.
[15] E. V. van Beek,et al. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI) , 2019, Pulmonary circulation.
[16] C. Ryerson,et al. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis , 2018, European Respiratory Journal.
[17] Anand Devaraj,et al. Role of imaging in progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.
[18] T. Welte,et al. More on idiopathic pulmonary arterial hypertension with a low diffusing capacity , 2017, European Respiratory Journal.
[19] D. Hansell,et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures , 2017, European Respiratory Journal.
[20] T. Welte,et al. Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.
[21] D. Hansell,et al. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT , 2015, Thorax.
[22] N. Westerhof,et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses , 2013, European Respiratory Journal.
[23] D. Lynch,et al. Interobserver variability in the CT assessment of honeycombing in the lungs. , 2013, Radiology.
[24] J. Wild,et al. Pulmonary hypertension in COPD: results from the ASPIRE registry , 2012, European Respiratory Journal.
[25] N. Müller,et al. Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.
[26] J. Butler,et al. Variability of routine pulmonary function tests. , 1975, Thorax.